Document is current

Article History

Received: 27 April 2026

Accepted: 3 June 2026

First Online: 20 June 2026

Declarations

:

: Dr. Jensen Yeung is an Editorial Board member of Dermatology and Therapy. Dr. Yeung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Yeung has been an advisor, consultant, speaker, or investigator for AbbVie, Allergan, Amgen, Arcutis, Astellas, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, Coherus, Dermavant, Forward, Galderma, GlaxoSmithKline, Incyte, Johnson & Johnson, Kyowa, LEO Pharma, Lilly, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, Sun Pharma, Takeda, UCB, and Xenon. Dr. Grewal is or has been an investigator, consultant, speaker, advisor for or received research funding or honoraria from AbbVie, Aralez, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Cipher, Dermtek, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Johnson & Johnson, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Stiefel, Sun Pharma, Tribute Pharmaceuticals, Takeda, and Vitae. Dr. Turchin served as consultant, speaker, or investigator for AbbVie, Amgen, Arcutis, Aristea, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Kiniksa, LEO Pharma, Mallinckrodt, Novartis, Pfizer, Sanofi, Sun Pharma, Takeda, and UCB. Dr. Mark Legault and Dr. Jason Stacey are employees of LEO Pharma Canada.

: The protocol for this study was reviewed and approved by the Advarra institutional review board (Pro00079506) and adhered to the principles of the Declaration of Helsinki of 1964 and its later amendments, Good Clinical Practice guidelines, and relevant laws and regulations. A waiver of Informed Consent was granted on the grounds that the study involved the secondary use of existing, deidentified data.